ライフサイエンスコーパス: acetonide

1 le to conversion to glycal 22 via the chloro acetonide.

2 effect on the cytotoxicity of triamcinolone acetonide.

3 olenic acid, 11-HLA) from (R)-glyceraldehyde acetonide.

4 e alone or in combination with triamcinolone acetonide.

5 ghtly long-lasting effect than triamcinolone acetonide.

6 roids such as dexamethasone and fluocinolone acetonide.

7 who were treated with inhaled triamcinolone acetonide (100 microg per puff).

8 thiophene, subsequent generation of the keto acetonide 12 followed by its Meerwein-Ponndorf-Verley re

9 emonstrated that panaxytriol and panaxytriol acetonide (12) moderately suppress tumor growth with lit

10 bizumab, 5386 bevacizumab, 935 triamcinolone acetonide, 121 pegaptanib sodium) were reviewed for 2465

11 duction of the ester and by formation of the acetonides 13bcd.

12 RPE-19 cells after exposure to triamcinolone acetonide (200 microg/mL) alone without the vehicle was

13 The R28 cells exposed to triamcinolone acetonide (200 microg/mL) without the vehicle also had a

14 per injection was 2 in 935 for triamcinolone acetonide, 3 in 9453 for ranibizumab, and 4 in 5386 for

15 Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevacizumab (32 eyes

16 Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevacizumab (32 eyes

17 perones in the presence of [3H]triamcinolone acetonide ([3H]TA), which binds to the receptor as GR.hs

18 riod of treatment with inhaled triamcinolone acetonide (400 microg twice per day).

19 They used inhaled triamcinolone acetonide, 600 mcg, or placebo, twice daily.

20 d by ester reduction and by formation of the acetonides 7bc.

21 Subjects were stabilized on triamcinolane acetonide (800 microg daily) and then enrolled in a 2-wk

22 synthesis of orthogonally protected Fmoc-Dyp-acetonide (9) and of several Fmoc-d-Hot horizontal lineT

23 18) derived from N-Boc-L-serine methyl ester acetonide (9), affording two novel ceramide analogues, (

24 in fact, engagement of the C9-C10 diol as an acetonide actually leads to notably enhanced cytotoxicit

25 Cyanohydrin acetonide alkylations were used to assemble the carbon s

26 re effective than intravitreal triamcinolone acetonide alone.

27 therapy with moderate doses of triamcinolone acetonide, an anti-inflammatory glucocorticoid, greatly

28 only in substrates that contain both a trans-acetonide and a tertiary amide substituent at C2.

29 of a 1,2-acetonide in the presence of a 1,3-acetonide and an (E)-selective olefination of an unstabl

30 Removal of acetonide and benzyl protecting groups afforded pure tri

31 I)-catalyzed reactions of (R)-glyceraldehyde acetonide and dibenzylamine with terminal alkynes provid

32 proved in 15 patients by using triamcinolone acetonide and in the remaining 15 patients by using infr

33 ds (budesonide, dexamethasone, triamcinolone acetonide, and dexamethasone acetate) ranged from 0.2 to

34 , chemical transformation into ecdysone 2, 3-acetonide, and mass spectrometry.

35 articles, blank nanoparticles, triamcinolone acetonide, and PBS groups following subconjunctival inje

36 ps (43% overall yield) from D-glyceraldehyde acetonide, and the cyclopentenone (+)-14, prepared in on

37 asone, mometasone furoate, and triamcinolone acetonide are pharmaceutical mainstays to treat chronic

38 Using glyceraldehyde acetonide as a chiral-pool precursor, an enantioselectiv

39 ds; intralesional injection of triamcinolone acetonide at the ulcer margin; topical cromolyn sodium;

40 coids (triamcinolone acetonide, fluocinolone acetonide, clobetasol propionate, and fluticasone propio

41 ed crystallinity compared to their five-ring acetonide counterparts.

42 The effects of triamcinolone acetonide cream 0.025% were assessed based on gene expre

43 The acetonide deprotection protocol described herein is expe

44 a high yielding, acid-mediated simultaneous acetonide deprotection-dithiane removal-ketalization pro

45 of DFT calculations, and the preparation of acetonide derivative 7a.

46 lute stereochemistry was determined on a bis-acetonide derivative using the variable temperature Mosh

47 adducts were confirmed by NMR analysis of 12 acetonide derivatives prepared from the corresponding 5,

48 Mass spectrometric analysis after acetonide derivatization also revealed that ester format

49 cycloaddition of cyclopent-2-en-1-one to the acetonide derived from enantiomerically pure and enzymat

50 ch has an altered affinity for triamcinolone acetonide, dexamethasone, and corticosterone.

51 tudy compared computer-modeled triamcinolone acetonide diffusion after posterior sub-Tenon's injectio

52 Treatment with topical triamcinolone acetonide dramatically reduced pathology but increased v

53 easible to construct a nontoxic fluocinolone acetonide drug delivery device that reproducibly release

54 The fluocinolone acetonide drug pellet can dislocate spontaneously from t

55 beclomethasone dipropionate or triamcinolone acetonide during a 2-wk, single-blind, run-in period wer

56 rticular injection of 40 mg of triamcinolone acetonide every 3 months on progression of cartilage los

57 c application of glucocorticoid fluocinolone acetonide (FA).

58 To investigate the effects of fluocinolone acetonide (FAc) on the progression to proliferative diab

59 our synthetic glucocorticoids (triamcinolone acetonide, fluocinolone acetonide, clobetasol propionate

60 Intravitreal triamcinolone acetonide followed by laser may be more effective than i

61 suspension releasing 5-FU and triamcinolone acetonide for 1 month.

62 200 microg/mL concentration of triamcinolone acetonide for 2, 6, and 24 hours.

63 mical modifications, including methanolysis, acetonide formation, and application of the modified Mos

64 o-step NMO-promoted osmylations bracketed by acetonide formation, and wholesale deprotection.

65 predicts efficient delivery of triamcinolone acetonide from the posterior sub-Tenon's space to the ex

66 protection of both terminal and internal N,0-acetonide functionalities.

67 o a cytosine aldehyde protected as the 2',3'-acetonide gave predominately the 5'R isomer, while phosp

68 In the triamcinolone acetonide group, 12 months after surgery the amplitude o

69 D-Glyceraldehyde acetonide has been used as the starting point for access

70 verse event associated with the fluocinolone acetonide implant (FAI), but no data are available regar

71 Sustained-release fluocinolone acetonide implant (Retisert) dissociation is a common oc

72 Twenty-seven sustained-release fluocinolone acetonide implant (Retisert) exchange or removal surgeri

73 7 consecutive sustained-release fluocinolone acetonide implant (Retisert) exchanges or removals betwe

74 Visual outcomes of fluocinolone acetonide implant and systemic treatment for intermediat

75 s with uveitis treated with the fluocinolone acetonide implant or standard systemic therapy.

76 surgically placed intravitreous fluocinolone acetonide implant or systemic corticosteroids supplement

77 that 75% of eyes receiving the fluocinolone acetonide implant required intraocular pressure (IOP) lo

78 These results suggest that fluocinolone acetonide implant therapy is associated with a clinicall

79 Fluocinolone acetonide implant therapy was associated with a greater

80 Fluocinolone acetonide implant therapy was reasonably cost-effective

81 munosuppression or intravitreal fluocinolone acetonide implant therapy.

82 rognosis with both systemic and fluocinolone acetonide implant treatment.

83 omized clinical trial comparing fluocinolone acetonide implant vs systemic corticosteroids and immuno

84 sociation between intravitreous fluocinolone acetonide implant vs systemic therapy and long-term visu

85 York, USA), a nonbiodegradable fluocinolone acetonide implant, was approved for use in noninfectious

86 than time to exchange of intact fluocinolone acetonide implants (70.5 vs 44.9 months; P < .001).

87 ] (aHR, 2.58); and prior use of fluocinolone acetonide implants (aHR, 9.75).

88 Fluocinolone acetonide implants can be considered, but have a high ri

89 mend that patients treated with fluocinolone acetonide implants receive frequent IOP monitoring and r

90 rds of 224 patients in whom 407 fluocinolone acetonide implants were placed by either of 2 surgeons b

91 Of 77 exchanged fluocinolone acetonide implants without dislocated pellets, 11 (14.2%

92 omized to receive intravitreous fluocinolone acetonide implants.

93 vice that reproducibly releases fluocinolone acetonide in a linear manner over an extended period.

94 y scale (DRSS) grade during the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) A and B Phase

95 l injections of bevacizumab or triamcinolone acetonide in patients with macular edema and cataract is

96 ctions are a selective deprotection of a 1,2-acetonide in the presence of a 1,3-acetonide and an (E)-

97 tone to prepare 2,2-dimethyl-1,3-dioxolanes (acetonides) in good to excellent yields.

98 In contrast, triamcinolone acetonide-induced luciferase activity was maximal at a d

99 ng suprachoroidal injection of triamcinolone acetonide injectable suspension (CLS-TA), in eyes with m

100 Intraoperative intravitreal triamcinolone acetonide injection induces earlier and marked exudative

101 Intravitreal triamcinolone acetonide injection therapy, in particular the 4-mg dose

102 1, 2, 3, 4, and 8 weeks) after triamcinolone acetonide injection, with 6 controls without injection.

103 cizumab injections, 35 (44.9%) triamcinolone acetonide injections, and 5 (6.4%) a dexamethasone impla

104 neficial treatment effects for triamcinolone acetonide, interferon alpha-2a, and supplemental oxygen;

105 A fluocinolone acetonide intravitreal implant (Retisert) was implanted

106 The fluocinolone acetonide intravitreal implant was approved by the Unite

107 Fluocinolone acetonide intravitreal implants are an effective therapy

108 Triamcinolone acetonide is toxic to proliferating cells of retinal ori

109 kness (CRT) after intravitreal triamcinolone acetonide (IVT) injection for macular edema secondary to

110 Intravitreal triamcinolone acetonide (IVTA) is an effective treatment for recalcitr

111 Study showed that intravitreal triamcinolone acetonide (IVTA) is effective at reducing macular edema

112 In 3 eyes, intravitreal triamcinolone acetonide (IVTA) was injected within 8 weeks prior to th

113 iodistribution and kinetics of triamcinolone acetonide, labeled with 11C, formulated and nasally admi

114 ior sub-Tenon's injection with triamcinolone acetonide levels in experimental undiluted vitreous and

115 eoretical model predicted that triamcinolone acetonide levels in systemic blood, vitreous, and choroi

116 such as trans-retinoic acid and fluocinolone acetonide, markedly inhibit both 12-O-tetradecanoylphorb

117 llen joints were injected with triamcinolone acetonide (maximum dosage 80 mg per month).

118 Intravitreal triamcinolone acetonide may be more effective than laser.

119 Hydrolysis of the acetonide moiety of 41, followed by oxidative cleavage o

120 injections of corticosteroid (triamcinolone acetonide [n = 16] or triamcinolone hexacetonide [n = 7]

121 ed 4 weeks after intramuscular triamcinolone acetonide: normalization of (1) symptoms (Asthma Control

122 resent method was also extended to deprotect acetonides obtained from 1,2-, and 1,3-terminal diols.

123 zolide 11b which, upon coupling with 2',3'-O-acetonide of AMP, afforded the acetonide of benzamide ad

124 with 2',3'-O-acetonide of AMP, afforded the acetonide of benzamide adenine dinucleotide (15) in 94%

125 The tricyclic acetonide of the dipeptide d-Hot horizontal lineTap is r

126 The acetonide of the protected amino acid cis-dihydroxyproli

127 ted cyclobutane was synthesized from the bis(acetonide) of d-glucose using dicyclopentadienylzirconiu

128 M peeling assisted with either triamcinolone acetonide or infracyanine green staining improves visual

129 al growth factor, intravitreal triamcinolone acetonide, or a combination of these therapies.

130 Intravitreal triamcinolone acetonide, pars plana vitrectomy, oral protein kinase C

131 cyclization reaction taking advantage of the acetonide pendant group.

132 he addition of vinyllithium reagent 7 to the acetonide-protected aldehyde 8 to access the carbon back

133 ohex-2-ene-1-one (3) has been developed from acetonide-protected meso-1,2-dihydrocatechol derivative

134 diol-based subunits were prepared from their acetonide-protected precursors (1a-4a).

135 A lithium enolate derived from an acetonide-protected pyroglutaminol undergoes a highly se

136 ME2 and 2-methoxyestradiol-15 alpha,16 alpha-acetonide, provided 29.4% and 26.7% inhibition of tumor

137 age of 1.6 posterior sub-Tenon triamcinolone acetonide (PSTA) injections in the 12 months preceding i

138 LH/HWE ester homologation as well as a novel acetonide rearrangement/glycal formation cascade.

139 Fluocinolone acetonide slow release implant (Iluvien(R)) was approved

140 However, triamcinolone acetonide staining is associated with an increase of fER

141 ssignment into 2 groups: 40-mg triamcinolone acetonide subacromial CSI versus 6 sessions of manual ph

142 conjunctival injection of 2 mg triamcinolone acetonide (TA) alone.

143 with the potent glucocorticoid triamcinolone acetonide (TA) and a fragment of the small heterodimer p

144 ansscleral drug delivery using triamcinolone acetonide (TA) as a model drug.

145 safety and pharmacodynamics of triamcinolone acetonide (TA) delivered by this technique.

146 GR activated by aldosterone or triamcinolone acetonide (TA) leads to significant transactivation of t

147 ugate of mitomycin C (MMC) and triamcinolone acetonide (TA) was synthesized using glutaric acid as a

148 examethasone (Dex), IL-10, and triamcinolone acetonide (TA) were used to antagonize proinflammatory s

149 nts-prednisolone acetate (PA), triamcinolone acetonide (TA), and lipid-based artificial tears (LBAT)-

150 and NONSA after intramuscular triamcinolone acetonide (TA), and to identify predictors of a corticos

151 00 microM CoCl(2), 1 microg/mL triamcinolone acetonide (TA), or both.

152 GR) and c-jun transcription in triamcinolone acetonide (TA)-treated AtT-20 cells.

153 electron-capture properties of triamcinolone acetonide (TAA) fatty acid conjugates were exploited for

154 Triamcinolone acetonide (TAA) is an anti-inflammatory steroid used for

155 Intra-articular administered triamcinolone acetonide (TAA) is one of the drug treatments employed t

156 g, H: 1,540 microg per day and triamcinolone acetonide (TAA) L: 400 microg, M: 800 microg, H: 1,600 m

157 the C21 acetate derivative of triamcinolone acetonide (TAA) under methane chemical ionization mass s

158 to quantify the low levels of triamcinolone acetonide (TACA) in porcine plasma following suprachoroi

159 Triamcinolone acetonide, the most commonly used intravitreal corticost

160 olipid analogues from D-mannitol 1,2:5,6-bis-acetonide to give two 1,1-difluorodeoxy analogues of (2R

161 a subconjunctival injection of triamcinolone acetonide to one eye.

162 ncapsulating the model steroid triamcinolone acetonide (Tr-A) were implanted subcutaneously in rats b

163 was observed in 4 intravitreal triamcinolone acetonide-treated patients (12%).

164 ented in 22 (69%) intravitreal triamcinolone acetonide-treated vs 11 (34%) intravitreal bevacizumab-t

165 In summary, the use of inhaled triamcinolone acetonide was associated with loss of BMD at the femoral

166 Carbon-11-labeled triamcinolone acetonide was formulated as the commercial product, and

167 th the vehicle alone, in which triamcinolone acetonide was suspended.

168 e P-450 3A (CYP3A) inducer] or triamcinolone acetonide (weak CYP3A inducer) produced dose-dependent i

169 derate potency steroids such as fluocinolone acetonide were inactive.

170 of a synthetic corticosteroid, fluocinolone acetonide, were constructed.

171 ma in response to intravitreal triamcinolone acetonide will be reviewed.

172 ve Suprachoroidal Injection of Triamcinolone Acetonide with Intravitreal Aflibercept in Subjects with

173 laser, or 4 mg of intravitreal triamcinolone acetonide with prompt laser.

174 he R28 cells were treated with triamcinolone acetonide with vehicle (200 microg/mL) for 24 hours (P <

175 nd R28 cells after exposure to triamcinolone acetonide with vehicle 200 microg/mL for 24 hours was 70

176 Triamcinolone acetonide with vehicle caused a greater reduction in cel

177 9 cells when treated with both triamcinolone acetonide, with or without the vehicle at a concentratio

178 erwent periocular injection of triamcinolone acetonide, with resolution of the subretinal fluid.

179 ase activity when treated with triamcinolone acetonide without the vehicle at any of the doses, but t